PA-EXONE
11.11.2021 14:33:09 CET | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the Schunk Group, an international technology company featuring products made of high-tech materials, including sintered metals, has purchased an X1 25Pro large metal binder jetting system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005667/en/
The new X1 25Pro metal printing system will be installed and used in the Schunk Sinter Metals location in Thale, Germany, to provide serial production of sintered metal parts to automotive, aerospace, medical, and other customers throughout Europe – starting with 316L stainless steel and later expanding to other materials.
“We believe 3D printing is the technology of the future, and we will use our binder jetting system to develop technologies and parts that go beyond what we can provide with traditional sintered metal components,” said Tobias Franz Heusel, Global Account Manager at Schunk.
Schunk plans to integrate its ExOne metal binder jetting technology into its industrial ecosystem that already includes other methods of 3D printing producing parts with different materials such as copper, stainless steel and low alloyed steel, as well as conventional manufacturing processes such as axial pressing and metal injection molding. “We believe binder jetting offers four primary advantages. In addition to speed and freedom of design, the ability to produce large volumes with 3D printing and a large selection of materials is fairly unique among 3D printing processes,” Heusel added.
Schunk selected ExOne as its binder jet partner, largely because of the company’s extensive history as the commercial pioneer and market leader in metal binder jetting. Over its history, ExOne has launched more than 10 commercial metal binder jetting systems.
“We are proud to partner with Schunk to provide ExOne binder jet 3D printing services in the European market,” said Eric Bader, Managing Director, ExOne, EMEA. “Schunk’s services will complement our own ExOne Adoption Center (EAC) in Gersthofen, where we will provide benchmarks to customers interested in purchasing machines.”
Details about Schunk’s move into binder jet 3D printing can be found at https://bit.ly/SchunkX1en
What is Binder Jet 3D Printing?
ExOne’s binder jet 3D printing transforms powdered materials – metal, sand or ceramic – into highly dense and functional precision parts at high speeds.
An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. ExOne now delivers high densities of greater than 97% for most metals, in line with Metal Injection Molding or gravity castings.
Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
Schunk Group
The Schunk Group is a global technology company. The company is a leading supplier of products made of high-tech materials – such as carbon, technical ceramics and sintered metal – as well as machines and systems – from environmental simulation and air conditioning to ultrasonic welding and optical machines. The Schunk Group has around 9,000 employees in 29 countries and achieved sales of €1.2 billion in 2020. Learn more at www.schunk-group.com or on LinkedIn @Schunk Group.
With over 90 years of experience in powder metallurgy, the business unit Schunk Sinter Metals is the technology and development partner for the automotive and aerospace industries when it comes to the production of sintered metal parts by axial pressing, metal powder injection molding and additive manufacturing processes. Learn more at www.schunk-mobility.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
